Status:
COMPLETED
Treating Refractory Major Depressive Disorder With Repetitive Transcranial Magnetic Stimulation
Lead Sponsor:
Centre for Addiction and Mental Health
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Studies exploring the efficacy of repetitive transcranial magnetic stimulation (rTMS) as a treatment for refractory major depressive disorder (MDD) have shown significant promise. Despite this, severa...
Detailed Description
Major Depressive Disorder (MDD) is one of the most prevalent mental illnesses in North America, affecting approximately 4% of Canadians annually. Though a number of effective treatments are available,...
Eligibility Criteria
Inclusion
- are voluntary and competent to consent based on their ability to provide a spontaneous narrative description of the key elements of the study (based on the MacCAT-CR)
- have a Structured Clinical Interview for DSM-IV (SCID) confirmed DSM-IV diagnosis of MDD with no co-morbid borderline personality disorder and/or antisocial personality disorder, as confirmed by the Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II)
- are between the ages of 18 and 85
- have failed to achieve a clinical response to at least 2 separate antidepressant trials of sufficient dose for at least 6 weeks, according to Stage II criteria outlined by Thase et al., or could not tolerate at least 2 trials of antidepressant medication
- have a score greater than or equal to 22 on the 17-item HAM-D
- no major, unstable medical and/or neurological conditions, such as seizures, stroke, hypertension, diabetes, coronary artery disease, thyroid problems, respiratory illness, allergies and presence of metal implants.
Exclusion
- have a history of DSM-IV substance dependence in the last 6 months, and have DSM-IV substance abuse in the last month
- history of self-harm behaviour in past 6 months
- have a concomitant major, unstable medical or neurologic illness, or have had a history of seizures
- are acutely suicidal
- are pregnant
- have metal implants
- are currently (or in the last 4 weeks) taking: (1) more than lorazepam 2 mg daily (or equivalent); (2) monoamine oxidase inhibitors; and/or (3)bupropion due to its associated increased risk for seizures.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00305045
Start Date
March 1 2005
End Date
May 1 2009
Last Update
January 24 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5T 1R8